BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Turkey's Erdogan denounces Israel-Greece-Cyprus trilateral summit, affirms support for Gaza- Idris Elba is the king of the stress-watch
- Several injured as man threatens attack on German high-speed train
- Putting pig organs in people is OK in the US, but growing human organs in pigs is not – why is that?
- Birds Will Flock To Your Birdbath When You Plant These Two Flowers Around It
- Here are 10 stores where you can get a free Thanksgiving turkey
- Illumina unveils dataset to speed up AI-powered drug discovery
- Benedict Cumberbatch takes on something even Sherlock can’t solve: male grief
- Find the Keys to Fruitful Venture The board: Conveying Results on Time
